

U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE			
<b>SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT</b>		Docket Number <b>13695/1</b>	
Application Number <b>10/574,917</b>	Filing Date <b>April 11, 2006</b>	Examiner <b>B. KWON</b>	Art Unit <b>1614</b>
Invention Title <b>USE OF L-BUTYLPHTHALIDE IN THE MANUFACTURE OF MEDICAMENTS FOR PREVENTION AND TREATMENT OF CEREBRAL INFARCT</b>		Inventors <b>Y. FENG et al.</b>	

Address:  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

I hereby certify that this correspondence is being electronically transmitted to the United States Patent and Trademark Office via the Office electronic filing system on **February 9, 2010**.

Signature: /Helen Tam/  
Helen Tam

Sir:

Pursuant to 37 CFR § 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. Unless otherwise indicated herein, one copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom. The filing of this Information Disclosure Statement and the enclosed PTO Form No. 1449, shall not be construed as an admission that the information cited is prior art, or is considered to be material to patentability as defined in 37 C.F.R. § 1.56(b). The paragraphs marked below are applicable. It is believed that no fees other than those indicated below are due, but authorization is hereby given to charge any additional fees due, or to credit any overpayment, to **Kenyon & Kenyon LLP, deposit account 11-0600**.

☒ 1. This Information Disclosure Statement is being filed (a) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53(d), (b) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application, (c) before the mailing date of a first Office Action on the merits in the present application, OR (d) before the mailing of a first office action after filing of a request for continued examination. No certification or fee is required.

☐ 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a final action, Notice of Allowance, or any action that otherwise closes prosecution.

☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

☐ c. Please charge the deposit account of **Kenyon & Kenyon LLP, Deposit Account No. 11-0600**, in the amount of \$180.00 for payment of the submission of Information Disclosure Statement under 37 CFR § 1.17(p) to ensure consideration of the disclosed information.

☐ 3. This Information Disclosure Statement is being filed after the mailing date of a final action, a Notice of Allowance, or any action that otherwise closes prosecution.

☐ a. I hereby certify that each item of information contained in this Information Disclosure Statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(1).

☐ b. I hereby certify that no item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 CFR §1.97(e)(2).

☐ c. Please charge the deposit account of **Kenyon & Kenyon LLP, Deposit Account No. 11-0600**, in the amount of \$180.00 for payment of the submission of Information Disclosure Statement under 37 CFR § 1.17(p) to ensure consideration of the disclosed information.

☒ 4. English-language Abstracts of the non-English language references are attached hereto.

Respectfully submitted,

Date: February 9, 2010

By: /King L. Wong/  
King L. Wong  
Reg. No. 37,500

KENYON & KENYON LLP  
One Broadway  
New York, NY 10004  
(202) 220-4200 (telephone)  
(202) 220-4201 (facsimile)  
**CUSTOMER NO. 26646**